Bio-Gene Technology Ltd.

As of June 30, 2026, Bio-Gene Technology Ltd. carries a market capitalization of 7.34M, placing it among publicly traded companies globally. Its enterprise value stands at 5.40M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Bio-Gene Technology Ltd.'s next confirmed earnings release is scheduled for March 3, 2027.

As of June 30, 2026, Bio-Gene Technology Ltd. has 386.08M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Bio-Gene Technology Ltd. maintains a current ratio of 4.78, meaning it holds 4.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Bio-Gene Technology Ltd. posted a negative return on equity (ROE) of -125.40, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -97.93, reflecting losses generated across the asset base.

As of the close on October 20, 2026, Bio-Gene Technology Ltd.'s stock has declined approximately 48.15% over the past 52 weeks. The 50-day moving average sits at 0.02, while the 200-day moving average is 0.03.

These figures cover the twelve months ended June 30, 2026. EBITDA reached -3.37M, while operating income came in at -3.41M.

These figures are as of June 30, 2026. Total book value stands at 2.09M, with working capital of 1.96M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -37.39, meaning Bio-Gene Technology Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.